乳腺癌骨转移患者骨代谢指标PICP、β-CTx与治疗效果的关系  

Relationship of bone metabolic indicators PICP and β-CTx with therapeutic effect in breast cancer patients with bone metastases

作　　者：宋斌斌 李侠 杨新妹 陈慧 周强 江一鸣 王爱芬 

机构地区：[1]嘉兴市第一医院肿瘤内科,浙江嘉兴314000

出　　处：《实用肿瘤杂志》2014年第3期228-230,共3页Journal of Practical Oncology

基　　金：嘉兴市科技局计划项目(SQ2012010090)

摘　　要：目的探讨骨代谢指标Ⅰ型胶原羧基端前肽(carboxyl-terminal propeptide of type1 procollagen,PICP)、β胶原降解产物(beta collagen degradation products,β-CTx)与乳腺癌骨转移患者治疗反应的关系。方法测定56例乳腺癌骨转移患者治疗前后骨代谢指标PICP和β-CTx,比较治疗前后骨代谢指标与治疗效果的关系,并进行随访。结果 56例乳腺癌骨转移患者中,临床获益组36例,治疗3月后PICP和β-CTx明显下降(P=0.016,P=0.001);病情进展组20例,治疗3月后PICP和β-CTx有所升高(P=0.008,P=0.042)。临床获益组中20例患者骨代谢指标先于影像学检查提示临床治疗有效。结论 PICP和β-CTx可作为乳腺癌骨转移患者评价疗效的辅助指标。Objective To investigate the relationship of bone metabolic indicators, carboxyl terminal propeptide of type I procollagen （PICP） and beta collagen degradation products （β-CTx）, with the therapeutic effect in breast cancer patients with bone metastases. Methods Fifty-six breast cancer patients with bone metastases were included in this study. Serum PICP and β-CTx were measured before and after treatment. The relationship between bone metabolic indicators and the therapeutic effect was analyzed. Results Among 56 patients, 36 were responders and 20 were non-responders. For responders, serum levels of PICP and β-CTx were significantly decreased after 3 months of treatment （P = 0. 016;P = 0. 001 ） ; while for non-responders both indicators were significantly raised （ P = 0. 008 ; P = 0.042 ）. In 20 responders, the reduction of PICP and β-CTx levels was observed earlier than the changes of imaging findings. Conclusion PICP and β- CTx may be used as indicators for efficacy assessment in treatment of breast cancer patients with bone metastases.

关 键 词：乳腺肿瘤 骨肿瘤 继发性 骨肿瘤 代谢 碱性磷酸酶 生物合成 前胶原 血液 肽碎片 代谢 胶原 血液 

分 类 号：R737.9[医药卫生—肿瘤]